Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Dyslipidaemia: Update Bulletin [May 2016]

Product Code:
596200540
Publication Date:
April 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Dyslipidaemia: Amgen’s new detailed data from the Phase III GAUSS-3 trial for Repatha; Sanofi and Regeneron’s Phase III ODYSSEY ESCAPE trial in heterozygous familial hypercholesterolaemia (HeFH) patients and Pfizer’s top-line data from the Phase III SPIRE-AI trial for bococizumab are also discussed.

Highlights from this event update bulletin

  • How do KOLs view the GAUSS 3 data in statin-intolerant patients with Repatha?
  • Why are KOLs not surprised with LDL-reductions in GAUSS 3 trial with the PCSK9 inhibitor?
  • How will GAUSS 3 data influence physician practice for patients treated with statins and ezetimibe?
  • How will ODYSSEY ESCAPE data impact aphaeresis treatment in HeFH patients? 
  • How do KOLs view Pfizer’s SPIRE 1 and SPIRE 2 trial for bococizumab? 
  • What safety concerns do experts have on the long-term safety and efficacy of PCSK9s?
  • As third to the market, Pfizer’s bococizumab compete in the market?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved